Work

Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Year: 2017

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood.v130.suppl_1.886.886

Authors: Partow Kebriaei, Matthias Stelljes, Daniel J. DeAngelo, Nicola Goekbuget, Hagop M. Kantarjian, Anjali S. Advani, Akil Merchant, Wendy Stock, Tao Wang, Hui Zhang, Fausto Loberiza, Erik Vandendries, David Marks

Institutions: The University of Texas MD Anderson Cancer Center, University Hospital Münster, Dana-Farber Cancer Institute, Goethe University Frankfurt, Cleveland Clinic, University of Southern California, USC Norris Comprehensive Cancer Center, University of Chicago, Pfizer (United States), Pfizer (China)

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2783329475

Cites:

Cited by: 6

Related to: 10